A Phase 1/2 Comparative Vaccine Trial of the Safety: ALVAC-HIV (vCP1521) Prime With Oligomeric gp160 (92TH023/LAI-DID) or Bivalent gp120 (CM235/SF2) Boost
2007
- Correction
- Cite
- Save
- Machine Reading By IdeaReader
0
References
4
Citations
NaN
KQI